- Home
- QGEN vs EXEL Comparison
QGEN vs EXEL Comparison
Compare QGEN & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QGEN
- EXEL
- Stock Information
- Founded
- QGEN 1986
- EXEL 1994
- Country
- QGEN Netherlands
- EXEL United States
- Employees
- QGEN N/A
- EXEL N/A
- Industry
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QGEN Health Care
- EXEL Health Care
- Exchange
- QGEN Nasdaq
- EXEL Nasdaq
- Market Cap
- QGEN 10.3B
- EXEL 10.4B
- IPO Year
- QGEN 1996
- EXEL 2000
- Fundamental
- Price
- QGEN $45.84
- EXEL $40.41
- Analyst Decision
- QGEN Buy
- EXEL Buy
- Analyst Count
- QGEN 8
- EXEL 22
- Target Price
- QGEN $51.01
- EXEL $44.00
- AVG Volume (30 Days)
- QGEN 1.3M
- EXEL 2.3M
- Earning Date
- QGEN 11-05-2025
- EXEL 10-28-2025
- Dividend Yield
- QGEN 3.32%
- EXEL N/A
- EPS Growth
- QGEN 405.09
- EXEL 81.76
- EPS
- QGEN 1.69
- EXEL 2.08
- Revenue
- QGEN $2,040,067,000.00
- EXEL $2,230,005,000.00
- Revenue This Year
- QGEN $7.22
- EXEL $9.19
- Revenue Next Year
- QGEN $5.66
- EXEL $12.54
- P/E Ratio
- QGEN $26.93
- EXEL $19.56
- Revenue Growth
- QGEN 5.15
- EXEL 10.73
- 52 Week Low
- QGEN $37.63
- EXEL $25.17
- 52 Week High
- QGEN $51.88
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- QGEN 39.86
- EXEL 61.99
- Support Level
- QGEN $45.18
- EXEL $38.37
- Resistance Level
- QGEN $46.18
- EXEL $40.78
- Average True Range (ATR)
- QGEN 0.67
- EXEL 1.01
- MACD
- QGEN -0.12
- EXEL 0.41
- Stochastic Oscillator
- QGEN 26.69
- EXEL 91.87
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.